Legalizing Cannabis To Impact Opioids Agonist Drugs Market Growth
The Global Opioids Market was valued at US$ 17,132.5 million in 2015 and is projected to expand at a CAGR of 4.2% during the forecast period (2016–2024), as highlighted in a new report published by Coherent Market Insights. Rising prevalence of chronic pain is expected to significantly support growth of the opioids market in the near future. According to American Legislative Exchange Council, in 2015, around 100 million people in the U.S. suffered from chronic pain, significantly more than the number of diabetic patients in the country.
Opioids are a class of drugs that include potential pain relievers prescribed legally and also includes the illegal drug heroin. Pain relieving drugs are chemically related with opioid receptors on nerve cells in the body. Use of prescribed opioid drug for a short period of time is safe for pain management. However, these drugs are frequently misused by taking the dose through a different route and in a greater quantity than the quantity actually prescribed, as they provide a sense of euphoria along with relieving pain. Such is the nature of opioid drugs that drug dependence can occur despite use as prescribed over prolonged use. Overdose of opioid pain relievers can be fatal. Furthermore, according to National Institute of Drug Abuse, there has been significant increase in deaths related to drug overdose, which involved the prescription opioid pain relievers and various federal and state laws have been applied to curb this epidemic. In 2011, the White House released an interagency strategy that focuses on federal agencies working in close coordination with states, education providers, parents, youth, patients and pharmacists. The main objective of the strategy is to increase awareness among the populace and across the value chain about consequences of prescription drug abuse and the requirement of appropriate prescribing, disposal and dispensing for effective prescription drug monitoring programs and also to enable exact medication disposal through prescription take-back initiatives.
Request for a sample copy @ https://www.coherentmarketinsights.com/insight/request-sample/135
Aggressive government strategies have led to fruition, with a noticeable decrease in prescription opioid drugs availability and lower number of case of deaths caused by overdose across various regions. While a large number of applications for opioids and its derivatives exist in the healthcare sector, research currently underway are expected to lead to several more novel applications of opioids. This in turn is projected to favor growth of the opioid market over the forecast period. Furthermore, chronic pain is a widespread problem and a major reason for rise significant potential for legally prescribed opioids such as morphine and codeine. According to British Journal of Anesthesia, in 2013, around 20% of the population in Europe suffered from chronic pain, leading to an estimated economic burden of over US$ 250 billion in Europe and around $150 billion per annum in the U.S.
The pain relieving segment is projected to gain significant traction over the forecast period, owing to the various new product launches and extensive R&D activities leading to major product advancements, which is further due to significant number of collaborations and acquisitions taking place in the opioids market. In 2015, Depomed, Inc.—a specialty pharmaceuticals company focused on products to treat pain and other neurological conditions—officially entered into a definitive agreement to acquire NUCYNTA—a Janssen Pharmaceuticals, Inc. franchise, in order to strengthen the pain management segment of the company. Furthermore, in 2016, China-based drug maker Humanwell Healthcare Group and PuraCap Pharmaceutical LLC.—a generic drug maker—entered into a definitive agreement to acquire 100% assets of Epic Pharma for US$ 550 Mn. This is expected to strengthen the company’s product portfolio by inclusion of drugs such as naltrexone and oxycodone hydrochloride.
Key takeaways of the market:
The global opioids market is expected to expand at a CAGR of 4.2% during the forecast period (2016–2024). Rising prevalence of chronic pain worldwide is expected to favor growth of the market for opioids over the forecast period.
The codeine segment in the global opioids market was estimated to be the largest in 2015 and is expected to dominate the market throughout the forecast period in terms of value.
By therapeutic application, opioids are expected to witness majority of the demand from pain management. The segment accounted for 79.6% of overall market revenue in 2015. Much of the demand generates from neuropathic pain.
Ask for customization: https://www.coherentmarketinsights.com/insight/request-customization/135
The global opioids market is characterized by strategic research and development and advancements in the technology of vaccines production. Also, the rise in adoption for poultry business globally is expected to favor the market for opioids market.
Some of the major players are Pfizer Inc., Purdue Pharma, Boehringer Ingelheim, Janssen Pharmaceuticals, Inc., Actavis Plc., Sanofi, Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Egalet Corporation, and Endo Pharmaceuticals Inc.
You may be interested
Hernia Repair Devices and Consumables Market Growth 2026Albert R - November 16, 2018
abdominal wall hernias include an Inguinal hernia, Femoral hernia, Umbilical hernia, Incisional hernia, Spigelian hernia, Obturator hernia, Epigastric hernia, Hiatal hernia, and diaphragmatic hernia. Most of the…
Gastrointestinal Devices Market Analysis & Outlook 2018-2026 | Top Players are Boston Scientific Corporation, Johnson & Johnson Ltd., Covidien Ltd., Fujinon Ltd., Stryker CorporationAlbert R - November 16, 2018
All bilaterians (animals having a bilateral symmetry) have a GI tract. Primarily, it is a tube that can transfer food to various organs of digestion. In case…
Opioids Market Growth Analysis By Top Players Purdue Pharma L.P., Janssen Pharmaceuticals, Inc., West – Ward Pharmaceuticals Corporation, Pfizer, Inc., Egalet Corporation, Allergan plc, Sanofi SA, Boehringer Ingelheim, and Sun Pharmaceutical Industries Ltd.Albert R - November 16, 2018
According to the American Academy of Pain Medicine (2011), the number of people who suffered from chronic pain was around 1.8 billion. Moreover, according to the NIH…